Niranjan Sardesai | President & Chief Executive Officer, Founder
Geneos Therapeutics

Niranjan Sardesai, President & Chief Executive Officer, Founder, Geneos Therapeutics

Dr. Sardesai founded Geneos after building Inovio Pharmaceuticals into a Phase III cancer and infectious disease immunotherapy company serving as its Chief Operating Officer. He held positions of increasing responsibility after joining the company in 2006 where he helped formulate the company’s product development and growth strategies and reorganized the company into a DNA vaccine and immunotherapies company. For Inovio, Dr. Sardesai drove multiple M&A and licensing transactions to consolidate key technologies, establish the corporate footprint, and develop its immunotherapies platform and product pipeline. He led the strategic out-licensing of Inovio’s pipeline products to secure major licensing deals totaling over $1 Bn with pharma partners. Dr. Sardesai was previously the founder and President of NVision Consulting Inc., a firm providing strategic counsel to entrepreneurial life sciences companies. He served as Director of Research and Development at Fujirebio Diagnostics, Inc., where he oversaw the expansion of the company’s oncology portfolio. Products developed under his leadership include groundbreaking new tests for mesothelioma (MESOMARKTM), bladder cancer and a multi-marker test for ovarian cancer (HE4). Dr. Sardesai received a PhD in Chemistry from the California Institute of Technology and a MBA from the Wharton School of the University of Pennsylvania, where he was the recipient of the Shils-Zeidman Award in Entrepreneurship. He was awarded fellowships at the Scripps Research Institute and the Massachusetts Institute of Technology (MIT). Dr. Sardesai received his Bachelor and Master of Science degrees in Chemistry from the Indian Institute of Technology, Bombay. Dr. Sardesai has authored over 120 peer-reviewed manuscripts and was recognized by PharmaVoice magazine as one of the top 100 most influential and inspirational leaders across the life sciences industry (2015).


Day 2 - Wednesday 3rd April @ 15:10

Clinical pipeline updates: Geneos Therapeutics

Day 2 - Wednesday 3rd April @ 17:10

Panel: Exploring the future prospects of cancer vaccines

  • Exploring the role and prospects of (neo)adjuvant cancer vaccines in the therapeutic landscape: adjuvant versus neoadjuvant, prevention of reoccurrence vs truly therapeutic, value in metastatic disease
  • Indications & immune characteristics: hot versus cold tumors & TME
  • Is there potential for off-the-shelf vaccines? What might this strategy look like?
last published: 30/Nov/23 11:25 GMT

back to speakers